[Experiences with an organ-saving and adjuvant-therapy concept in stage 1 breast cancers after 6 years of use within the scope of a controlled clinical study].
Between 1979 and 1983 56 women with stage I breast cancer underwent tumorectomy plus lymphadenectomy, postoperative irradiation and adjuvant antioestrogen therapy in cases of hormone receptor positive tumours. All patients with hormone receptor negative tumours received 6 cycles of combined CMF chemotherapy instead of antioestrogen therapy. It was possible to complete optimal dosage of CMF or tamoxifen in more than 85% of our patients. Leukopenia occurred in only 3 patients given chemotherapy, whilst intolerable gastrointestinal side effects occurred in 4 patients given antioestrogen therapy. No interference was detected between irradiation and chemo- or hormone therapy and no serious local complications with functional impairment were registered. 23% of the women had positive axillary nodes at the time of operation. The preoperative staging proved incorrect in 16% of cases, the tumour size exceeding 2 cm. After a mean follow-up period of 36 months the local recurrence rate was 3.6% and distant metastases appeared in 9% of patients, whereby there was a significant dependence on lymph node status. No patient died of cancer during the observation period. In view of the hypothesis that breast cancer is a systemic disease more attention should be paid to local cosmetic results and to systemic adjuvant therapy.
D000230:Adenocarcinoma / Q000601:surgery; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D002277:Carcinoma / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000601:surgery; D002986:Clinical Trials as Topic; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008408:Mastectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D009367:Neoplasm Staging; D011867:Radioisotope Teletherapy
D003037:Cobalt Radioisotopes
Erfahrungen mit einem organerhaltenden und adjuvanten Therapiekonzept bei Mammakarzinomen im Stadium 1 nach 6jähriger Anwendungsdauer im Rahmen einer klinisch kontrollierten Studie.